2006 17 155-162 sibutramine orlistat rimonabant ( Anti-obesity agents ) Sibutramine Orlistat Rimonabant 5 12 15 1980 1986 1996 12.4% 14.8% 15.6% 10.1% 11.1% 12.9% ( metabolic syndrome ) 1993-1996 10.5% 2000-2001 15.9% 13.7% 10.7%1 2 2-4 704 138 156 BMI mulating hormone ( -MSH ) -MSH BMI menalocortin-4 ( MC4-R ) 27kg/m2 BMI <27 POMC 24kg/m2 6 MC4-R 11-13 Prader-Willi ( leptin resistance ) 14 Albright hereditary osteodystrophy Fragile X adiponectin resistin interleukin 6 ( IL-6 ) tumor necrosis fac- tor-alpha ( TNF- ) visfatin arcuate nu- cleus neuropep- tide Y ( NPY ) agouti-related peptide ( AgRP ) Ghrelin proopiomelanocortin ghrelin ( POMC ) cocaine-and amphetamine-regulated NPY AgRP transcript ( CART ) 15 ghrelin 16,17 18 7 ghrelin Cannabinoid system cholecystokinin glucagon-like peptide 1 ( GLP-1 ) pancreatic ( receptors ) polypeptide amylin peptide YY cannabinoid receptor 1 ( CB1 ) cannabinoid re- ceptor 2 ( CB2 ) CB1 CB2 cannabinoid system 8 CB1 9 CB1 blockage CB1 blockage ( ) ( ) 10 ( leptin ) ( leptin receptor ) POMC -melanocyte-sti- 157 Sibutramine 2 15 mg sibutramine 2 12 sibutra- mine 0.3 mmol/l 1.4 mmol/l ( p=0.04 ) Sibutramine ( Reductil® ® ) sibutramine 0.3% 0.0% Sibutramine ( p<0.05 ) 1.0% sibu- serotonin norepinephrine tramine 33% 5% ( SNRI ) ( p<0.05) 5% sibutramine 19% 0% ( fat mass ) sibutramine 7 1047 1.0% 0.0%( p<0.05 ) 24 24 1.8kg 0.2kg ( p<0.001 ) 24 1.2% Sibutramine sibutramine 1 mg 2.7% 5 mg 5 mg- 3.9% 10 mg 6.1% 15 mg 30 mg 7.4% 20 mg 8.8% 30 mg 10 mg 9.4% 4 15 mg 24 19 10 mg 5 mg 12 10 mg-15 mg 3-6 1.4±0.5kg sibutramine 5mg 4 mmHg 1% 2.4±0.5kg sibutramine 10 mg 25 5.1±0.5kg sibutramine 15 mg 4.9± 0.5kg 20 sibu- sibutramine tramine 21 Orlistat ( Xenical® ® ) 29 Orlistat sibutramine 10 20 mg/day sibutramine 3 l 2.78kg 4.45 kg 22 26 15 743 sibutramine 15 mg orli- stat 120 mg Orlistat 12.1±9.8kg 10.2% ( 10.3kg ) sibutramine 5.0±7.4kg 6.1% ( 6.2kg ) 6.7±7.9kg orlistat orlistat 76% 23 158 84% 6.6kg ( p<0.001 ) rimonabant 20mg orlistat 5% 10% 0.9kg HDL 2.5kg 27 triglyceride orlistat ( 12.9% ) ( 7.2% ) ( 8.7% ) orlistat 2.6% 10.4%28 orlistat 2 ( RIO- orlistat 6.2±0.45% North America )33 RIO-Europe 4.3±0.49% 5% rimonabant 20 mg orlistat 6.3kg 49% 23%29 1.6kg ( p<0.01 ) ( XENDOS ) HDL triglyceride BMI 30 rimonabant 20 mg orlistat 2 rimonabant 20 mg 9.0% orlistat 6.2% orlistat ( 11.2% ) 37.3% 3.0 kg orlistat 5.8kg ( p<0.001 ) 30 Orlistat (RIO-Lipid ) 34 rimonabant 79% orlistat 59% 5 mg 20 mg ( ) 4.2kg ( p<0.001 ) 8.6kg ( p<0.001 ) ( ) 31 rimonabant 20mg A D E beta- triglyceride leptin orlistat HDL beta- 8,10,12 adiponectin LDL Orlistat 120 mg LDL CRP orlistat rimonabant A D E 2 ( 12.7% ) ( 10.4% ) ( 9.5% ) ( 8.7% ) ( 7.2% ) Rimonabant ( Acomplia® ) ( 6.4% ) Rimonabant cannabinoid receptor 1 rimonabant ( CB1 ) blockage ( RIO-Europe ) 32 rimonabant BMI 30kg/m2 BMI 27kg/m2 35,36 FDA rimonabant 5 mg 20 mg 3.4kg ( p=0.002 ) Exenatide ( Byetta® ) glucagon-like peptide 159 1 ( GLP-1 ) 2005 H3R 55 H3R antago- nist 56 37-39 ghrelin Neuropeptide Y ( NPY ) 40 ghrelin ( receptor NPY Y1 receptor ( NPY Y1R ) antagonist ) ghrelin R- 57 NPY NA ( anti-sense mRNA ) ghrelin Y1R antagonist 41-43 58 ghrelin ghre- PPAR lin fibrate PPAR Ciliary neurotrophic factor ( CNTF ) agonist PPAR agonist 59,60 CNTF CNTF PPAR agonist 61 PPAR agonist TZD CNTF ( re- combinant human variant ) CNTF ( rhvCNTF ) 44 PPAR antagonist Pramlintide ( Symlin® ) amylin PPAR antagonist 2005 62,63 PPAR 1 2 45-48 topiramate zonisamide bupro- 3 adrenergic receptor agonist pion fluoxetine sertraline dia- zoxide aromatase inhibitor 49 L-796568 ( 3 adrenergic D receptor agonist ) 50, 51 3 adrenergic receptor agonist sibu- Melanocortin melanocyte-stimulating hor- tramine orlistat rimonabant mone/adrenocorticotropin4–10 ( MSH/ACTH4–10 ) melanocortin-4 receptor ( MC4-R ) agonist MC4-R 52 53 54 Histamine H3 receptor ( H3R ) 64 160 15.Kamegai J, Tamura H, Shimizu T, Ishii S, Sugihara H, Wakabayashi I. Chronic central infusion of ghrelin increases hy- pothalamic neuropeptide Y and agouti-related protein mRNA levels and body weight in rats. Diabetes 2001; 50: 2438-43. 16.Tschop M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. Nature 2000; 407: 908-13. 17.Wren AM, Seal LJ, Cohen MA, et al. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 1.Chu NF. Prevalence of obesity in Taiwan. Obesity Rev 2005; 6: 2001; 86: 5992-5. 271-4. 18.Druce MR, Wren AM, Park AJ, et al. Ghrelin increases food in- 2.Tai TY, Chuang LM, Wu HP, Chen CJ. Association of body build take in obese as well as lean subjects. Int J Obes 2005; 29: 1130- with non-insulin-dependent diabetes mellitus and hypertension 6. among Chinese adults: a 4-year follow-up study. Int J Epidemiol 19.Bray GA, Blackburn GL, Ferguson JM, et al. Sibutramine pro- 1992; 21: 511-7. duces dose-related weight loss. Obes Res 1999; 7: 189-98. 3.Wei JN, Sung FC, Lin CC, Lin RS, Chiang CC, Chuang LM. 20.Hanotin C, Thomas F, Jones SP, Leutenegger EP, Drouin P. National surveillance for type 2 diabetes mellitus in Taiwanese Efficacy and tolerability of sibutramine in obese patients: a dose- children. JAMA 2003; 290: 1345-50. ranging study. Int J Obes Relat Metab Disord 1998; 22: 32-8. 4.Changa CJ, Lua FH, Yanga YC, et al. Epidemiologic study of 21.Apfelbaum M, Vague P, Ziegler O, Hanotin C, Thomas F, type 2 diabetes in Taiwan. Diabetes Res Clin Pr 2000; 50: S49- Leutenegger E. Long-term maintenance of weight loss after a 50. very-low-calorie diet: a randomized blinded trial of the effica- 5.Poirier P, Giles TD, Bray GA, et al. Obesity and cardiovascular cy and tolerability of sibutramine. Am J Med 1999; 106: 179- disease: pathophysiology, evaluation, and effect of weight loss: 84. an update of the 1997 American Heart Association scientific 22.Arterburn DE, Crane PK, Veenstra DL. The efficacy and safety statement on obesity and heart disease from the obesity com- of sibutramine for weight loss: a systematic review. Arch Intern mittee of the council on nutrition, physical activity, and Med 2004; 164: 994-1003. metabolism. Circulation 2006; 113: 898-918. 23.Wadden TA, Berkowitz RI, Womble LG, et al. Randomized tri- 6. 91 al of lifestyle modification and pharmacotherapy for obesity. N 4 2002 ( http://www.doh.gov.tw ) Engl J Med 2005; 353: 2111-20. 7.Huda MSB, Wilding JPH, Pinkney JH. Gut peptides and the 24.Finer N, Bloom SR, Frost GS, Banks LM, Griffiths J. regulation of appetite. Obesity Rev 2006; 7: 163-82. Sibutramine is effective for weight loss and diabetic control in 8.Marzo VD, Bifulco M, Petrocellis LD. The endocannabinoid obesity with type 2 diabetes: a randomised, double-blind, place- system and its therapeutic exploitation. Nat Rev Drug Discov bo-controlled study. Diabetes Obes Metab 2000; 2: 105-12. 2004; 3: 771-84. 25.McNeely W, Goa KL. Sibutramine: a review of its contribution 9.George K, Sandor B. Novel physiologic functions of endo- to the management of obesity. Drugs 1998; 56: 1093-124. cannabinoids as revealed through the use of mutant Mice. 26.Drent ML, Larsson I, William-Olsson T, et al. Orlistat (Ro 18- Neurochem Res 2001; 26: 1015-21. 0647), a lipase inhibitor, in the treatment of human obesity: a 10.Cota D, Marsicano G, Tschop M, et al. The endogenous cannabi- multiple dose study. Int J Obes Relat Metab Disord 1995; 19: noid system affects energy balance via central orexigenic drive 221-6. .. .. and peripheral lipogenesis. J Clin Invest 2003; 112: 423-31. 27.Sjostrom L, Rissanen A, Andersen T, et al. Randomised place- 11.Steven BH, Andrew SG, Ken F, et al. Recombinant leptin for bo-controlled trial of orlistat for weight loss and prevention of weight loss in obese and lean adults: a randomized, controlled, weight regain in obese patients. Lancet 1998; 352: 167-72. dose-escalation trial. JAMA 1999; 282: 1568-75. 28.Rissanen A. Pharmacological intervention: the antiobesity ap- 12.Hukshorn CJ, Westerterp-Plantenga MS, Saris WH. Pegylated proach. Eur J Clin Invest 1998; 28: 27-30. human recombinant leptin (PEG-OB) causes additional weight 29.Hollander PA, Elbein SC, Hirsch IB, et al. Role of orlistat in the loss in severely energy-restricted, overweight men. Am J Clin treatment of obese patients with type 2 diabetes. A 1-year ran- Nutr 2003; 77: 771-6. domized double-blind study. Diabetes Care 1998; 21: 1288-94. 13.Licinio J, Caglayan S, Ozata M, et al. Phenotypic effects of lep- 30.Jarl ST, Jonathan H, Mark NB, Lars S. XENical in the Prevention tin replacement on morbid obesity, diabetes mellitus, hypogo- of Diabetes in Obese Subjects (XENDOS) Study: A random- nadism, and behavior in leptin-deficient adults. Proc Natl Acad ized study of orlistat as an adjunct to lifestyle changes for the Sci 2004; 101: 4531-6. prevention of type 2 diabetes in obese patients. Diabetes Care 14.Considine RV, Sinha MK, Heiman ML, et al. Serum im- 2004; 27: 155-61. munoreactive-leptin concentrations in normal-weight and obese 31.Michael HD, Jonathan H, Mario D, et al.